2. Immunology/Inflammation
  3. Transmembrane Glycoprotein
  4. VIS832

VIS832 is an anti-CD138 monoclonal antibody. VIS832 induces antibody-dependent cellular cytotoxicity. VIS832 inhibits the growth of disseminated multiple myeloma tumors in vivo. VIS832 exerts anti-tumor effects on multiple myeloma in combination with Lenalidomide (HY-A0003) or Bortezomib (HY-10227). VIS832 can be used in research related to multiple myeloma.

For research use only. We do not sell to patients.

VIS832

VIS832 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

VIS832 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

VIS832 is an anti-CD138 monoclonal antibody. VIS832 induces antibody-dependent cellular cytotoxicity. VIS832 inhibits the growth of disseminated multiple myeloma tumors in vivo. VIS832 exerts anti-tumor effects on multiple myeloma in combination with Lenalidomide (HY-A0003) or Bortezomib (HY-10227). VIS832 can be used in research related to multiple myeloma[1].

Species Reactivity

Human
In Vitro

VIS832 (0.01-10 μg/mL) efficiently binds to CD138 expressed on multiple myeloma (MM) cell lines (MM1S, MM1R, H929, U266, OPM2, RPMI8226, JJN3, MOLP8) and primary MM cells, with an affinity in the sub-nanomolar to low nanomolar range. Moreover, its binding capacity is significantly stronger than that of the anti-CD138 antibody BB4[1].
VIS832 (0.0001-100 μg/mL) exerts potent antibody-dependent cell-mediated cytotoxicity (ADCC) against U266 multiple myeloma (MM) cells, with an EC50 of approximately 99.31 ng/mL (0.66 nM). Defucosylated VIS832 shows enhanced potency, with an EC50 of 28.67 ng/mL (0.2 nM) and a >7-fold increase in maximum lytic activity[1].
VIS832 (0-10 μg/mL) induces potent, dose-dependent antibody-dependent cell-mediated cytotoxicity (ADCC) against 12 multiple myeloma (MM) cell lines, with EC50 values ranging from 2.22 to 15.3 ng/mL, and the bone marrow microenvironment exerts minimal impact on this activity[1].
VIS832 (0-10 μg/mL; 24 h) induces dose-dependent, CD138-specific autologous antibody-dependent cell-mediated cytotoxicity (ADCC) against primary multiple myeloma (MM) cells, with an EC50 value of 8.58-86.04 ng/mL, and achieves a maximum lysis rate of >60% across all tested samples[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

VIS832 Related Antibodies
In Vivo

Monotherapy with VIS832 (4 mg/kg; i.p.; twice weekly; for 52 days) significantly inhibits tumor growth of disseminated multiple myeloma in CB-17 SCID mice and extends the median survival to >60 days, whereas combination treatment with Bortezomib (HY-10227) induces complete tumor regression, with 100% survival rate of mice on day 73[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CB-17 SCID (9 mice per group; multiple myeloma model via intravenous injection of MM1S-luc cells)[1]
Dosage: 4 mg/kg (monotherapy); 4 mg/kg + 1 mg/kg bortezomib (combination)
Administration: i.p.; twice weekly; 52 days
Result: Reduced disseminated tumor growth.
Prolonged median survival to >60 days (vs. 30 days for vehicle control).
Achieved a tumor growth delay of 13.9 days, a median % ΔT/C of 1.1% on day 36, 22.2% complete tumor regression, and 56% of mice remained on study until day 73.
Observed significant survival benefit at day 53 (P < 0.0001 vs. vehicle control), and efficacy was sustained after treatment discontinuation.
Induced complete tumor regression in 100% of mice when combined with bortezomib, resulted in >90% tumor-free survivors, and 100% survival to day 73, with a tumor growth delay of >45 days and median % ΔT/C of 0.0% on day 36.
Gene ID

6382  [NCBI]

Accession
Target

Syndecan-1/CD138
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

VIS832 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

VIS832VIS 832VIS-832Transmembrane GlycoproteinNK cellshuman MM cell linesmultiple myeloma tumorsbortezomibmultiple myeloma cellsmacrophagesCD138lenalidomideCB-17 SCID miceprimary patient MM cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
VIS832
Cat. No.:
HY-P992483
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.